Industry News
Pharmaceutical Industry News
Amid efforts on several fronts to…
Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price.
AstraZeneca is giving Pascal…
AstraZeneca is giving Pascal Soriot a pay raise as the longtime CEO weathered a year of “significant geopolitical uncertainty” to advance the British pharma toward an ambitious 2030 goal.
Just three months after further…
Just three months after further scaling back its support for the struggling hemophilia A gene therapy Roctavian, the company is walking away altogether by pulling the treatment from the market.
GenEdit is sailing toward the…
GenEdit is sailing toward the clinic with a new name and fresh funding. Rebranded as BreezeBio, the biotech has raised $60 million to take a drug candidate designed to restore immune tolerance in Type 1
Looking to gain an edge as its…
Looking to gain an edge as its broader obesity ambitions take shape, Pfizer has picked up the rights to a recently approved GLP-1 in China, unlocking an immediate commercial opportunity in type 2 diabetes, with
The family of a Baltimore woman…
The family of a Baltimore woman whose cells were extracted for medical research without her consent 75 years ago has settled a lawsuit with Novartis, with terms of the agreement confidential. Lawsuits the estate has
Four years after the FDA issued…
Four years after the FDA issued its most heavy-handed form of a rejection to pegzilarginase, the U.S. regulator has given the same treatment a thumbs-up. Scoring an accelerated nod is Immedica Pharma for Loargys as
Havas will lead Indivior’s…
Havas will lead Indivior’s integrated strategy, creative, media and digital efforts across healthcare professional and direct-to-consumer audiences.
With a new corporate sponsorship…
With a new corporate sponsorship in hand, Ardelyx is aiming for a hole-in-one in the awareness-raising game.
The new plants are the latest in a…
The new plants are the latest in a string of recent investments AbbVie has made in U.S. manufacturing, filling out the company's plan to infuse $100 billion into its American operations over the next decade.
Roche’s Enspryng is making solid…
Roche’s Enspryng is making solid progress as a treatment for neuromyelitis optica spectrum disorder. But the company’s efforts to expand its use to a new indication is coming up short.
With the Supreme Court’s rebuke…
With the Supreme Court’s rebuke of President Donald Trump’s emergency tariffs Friday, the U.S. administration’s international trade agenda is facing a new threat. At least one major partner has pumped the brakes on a deal
Bayer has filed a false…
Bayer has filed a false advertising lawsuit taking issue with claims made by Johnson & Johnson to pit their prostate cancer drugs against one another.
With a productive working…
With a productive working relationship between the two companies already well established, Bora Pharmaceuticals is renewing a $250 million global manufacturing agreement with British drugmaker GSK.
Vanda Pharmaceuticals is riding a…
Vanda Pharmaceuticals is riding a regulatory roller coaster over the last few months with two FDA approvals and one rejection. On Friday, the U.S. regulator signed off on Vanda's Bysanti, an atypical antipsychotic treatment for
The patent cliff for Keytruda is…
The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming medicines
The trend of rising FDA voucher…
The trend of rising FDA voucher prices is continuing as 2026 plays out, with another transaction now valued at $200 million or more.
What to Know Before Buying Weight Loss Drugs Online
Many patients are getting GLP-1s from websites and medical spas. But there’s much less oversight.
About a month after securing a…
About a month after securing a label expansion from the FDA for multidose pen versions of Zepbound, Eli Lilly is making the KwikPens available to self-paying users of its direct-to-consumer drug sales platform.
Catalent is cutting more roles at…
Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. This round of layoffs will affect 93 employees at the Harmans facility and three more in nearby Baltimore.